<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356148</url>
  </required_header>
  <id_info>
    <org_study_id>MAR-YC-2003-0111</org_study_id>
    <nct_id>NCT00356148</nct_id>
  </id_info>
  <brief_title>The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.</brief_title>
  <official_title>Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marmara University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center trial to compare the rate of surgical site infection (SSI) in normal
      (BMI equal to or less than 25; Control Group)) and overweight (BMI over 25) women who are
      undergoing breast cancer surgery. The overweight patients are further randomized into two
      groups; in one group patients receive prophylactic antibiotics (ampicillin/sulbactam;
      Prophylaxis Group), in the other they do not (No Prophylaxis Group).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONTEXT Although breast surgery is regarded as clean surgery, the actual SSI rate is well
      above accepted range in various series. Retrospective studies showed BMI as one of the
      factors which may have caused increased SSI rate after breast cancer surgery. Yet, no
      prospective randomized study assessed the efficacy of chemoprophylaxis during breast surgery
      in overweight patients.

      OBJECTIVE To compare the SSI rate between three groups of early stage breast cancer patients
      in which two are assigned according to randomization. First, patients are grouped into two
      according to their BMI. All patients (Control Group) with BMI equal to or below 25 do not
      receive any antibiotics as prophylaxis. Patients with a BMI above 25 are randomly assigned to
      receive a single dose prophylactic ampicillin /sulbactam combination before surgery
      (Prophylaxis Group) or not to receive chemoprophylaxis (No Prophylaxis Group).

      DESIGN, SETTING AND PATIENTS Patient recruitment is still continuing after the study started
      in October 2003 in order to reach a sample size of 360 patients with BMI over 25. Advanced or
      distant metastatic stage, receiving neoadjuvant therapy, history of receiving antibiotics
      within prior 3 months, history of immunodeficiency, having a remote infection and history of
      reaction to treatment antibiotics are within the exclusion criteria.

      INTERVENTIONS All patients are followed for 30 days postoperatively (once in a week at the
      original surgical unit). Patients and the investigator who inspects all wounds are blinded.
      Cost of SSI-related prophylaxis and treatments (including additional hospital visits after
      discharge, physician charges, additional antibiotics, wound management, other drugs and
      interventions etc) is calculated in each study group and compared with each other.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group).</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall SSI-related Prophylaxis and Treatment Cost in Patients With BMI Over 25 Who Received Prophylaxis (Prophylaxis Group) and Not (No Prophylaxis Group).</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Prophylaxis Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Prophylaxis Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who are BMI over 25 and do not receive antibiotic prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin/Sulbactam</intervention_name>
    <description>Ampicillin/Sulbactam 1 gr, once within onr hour before surgery</description>
    <arm_group_label>Prophylaxis Group</arm_group_label>
    <other_name>Ampisid 1 gr</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women at any age with early stage breast cancer (stage I-II) and American Society of
             Anesthesiologists (ASA) score of I-II.

        Exclusion Criteria:

          -  Ductal carcinoma in situ (DCIS; stage 0 cancer),

          -  Advanced or distant metastatic stage,

          -  Receiving any neoadjuvant therapy,

          -  History of receiving any antibiotics within prior 3 months,

          -  History of immunodeficiency,

          -  Having a remote infection,

          -  History of reaction to study antibiotics,

          -  Denial of signing the consent form.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bahadir M Gulluoglu, MD, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>Marmara University School of Medicine, Department of General Surgery, Breast and Endocrine Surgery Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marmara University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Cunningham M, Bunn F, Handscomb K. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005360. Review. Update in: Cochrane Database Syst Rev. 2012;1:CD005360.</citation>
    <PMID>16625637</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <results_first_submitted>April 20, 2012</results_first_submitted>
  <results_first_submitted_qc>December 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2013</results_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marmara University</investigator_affiliation>
    <investigator_full_name>Bahadir M. Gulluoglu, M.D.</investigator_full_name>
    <investigator_title>Prof Bahadir M Gulluoglu, MD, FACS</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>breast surgery</keyword>
  <keyword>clean wound</keyword>
  <keyword>overweight</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Sultamicillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at a tertiary university teaching hospital between October 2003 and March 2010.</recruitment_details>
      <pre_assignment_details>Patients having male gender, diagnosis of Stage 0, locally advanced or bilateral breast cancer, receiving neoadjuvant treatment, planning to undergo reconstructive surgery, having immunodeficiency, receiving antibiotics during previous one month, undergoing breast / axilla operation before randomization, denying to provide consent were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prophylaxis Group</title>
          <description>patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis</description>
        </group>
        <group group_id="P2">
          <title>No Prophylaxis Group</title>
          <description>Patients who are BMI over 25 and do not receive antibiotic prophylaxis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Reoperation within 30 days</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prophylaxis Group</title>
          <description>patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis</description>
        </group>
        <group group_id="B2">
          <title>No Prophylaxis Group</title>
          <description>Patients who are BMI over 25 and do not receive antibiotic prophylaxis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="372"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.1" spread="11.1"/>
                    <measurement group_id="B2" value="56.9" spread="14.1"/>
                    <measurement group_id="B3" value="57.5" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group).</title>
        <time_frame>1 month</time_frame>
        <population>Analysis was intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis Group</title>
            <description>patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>No Prophylaxis Group</title>
            <description>Patients who are BMI over 25 and not receive antibiotic prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group).</title>
          <population>Analysis was intent-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall SSI-related Prophylaxis and Treatment Cost in Patients With BMI Over 25 Who Received Prophylaxis (Prophylaxis Group) and Not (No Prophylaxis Group).</title>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis Group</title>
            <description>patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>No Prophylaxis Group</title>
            <description>Patients who are BMI over 25 and not receiving antibiotic prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Overall SSI-related Prophylaxis and Treatment Cost in Patients With BMI Over 25 Who Received Prophylaxis (Prophylaxis Group) and Not (No Prophylaxis Group).</title>
          <units>Monetary unit in Turkish Liras</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="5.6"/>
                    <measurement group_id="O2" value="13" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prophylaxis Group</title>
          <description>patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis</description>
        </group>
        <group group_id="E2">
          <title>No Prophylaxis Group</title>
          <description>Patients who are BMI over 25 and do not receive antibiotic prophylaxis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Bahadir M Gulluoglu</name_or_title>
      <organization>Marmara University School of Medicine</organization>
      <phone>902164256565 ext 4012</phone>
      <email>bmgulluoglu@marmara.edu.tr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

